Cargando…

The Effect of Infliximab on Patients with Ulcerative Colitis in Korea

BACKGROUND/AIMS: Infliximab was introduced recently as a rescue therapy for ulcerative colitis (UC) patients refractory to conventional treatments such as therapy with 5-amiono salicylic acids (5-ASA), immune modulators, and corticosteroids. However, there is insufficient data about its efficacy and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seo, Hyun Il, Park, Dong Il, Kim, Tae Oh, Kim, You Sun, Lee, Suck-Ho, Kim, Ji Won, Kim, Jae Hak, Shin, Jeong Eun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Association for the Study of Intestinal Diseases 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204725/ https://www.ncbi.nlm.nih.gov/pubmed/25349595 http://dx.doi.org/10.5217/ir.2014.12.3.214

Ejemplares similares

Comparison of Long-term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis
por: Lee, Yong Il, et al.
Publicado: (2021)

Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study
por: Kim, Eun Hye, et al.
Publicado: (2015)

Infliximab versus Adalimumab, Which One Is Better for Ulcerative Colitis?
por: Kim, Eun Soo
Publicado: (2021)

A Type II Segmental Vitiligo Developed under Infliximab Treatment for Ulcerative Colitis
por: Ryu, Tae Hyung, et al.
Publicado: (2017)

The real-world outcomes of vedolizumab in patients with ulcerative colitis in Korea: a multicenter retrospective study
por: Ye, Byong Duk, et al.
Publicado: (2021)

Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis
por: Oh, Shin Ju, et al.
Publicado: (2021)

Prognostic Value of Terminal Ileal Inflammation in Patients with Ulcerative Colitis
por: Yu, Jongwook, et al.
Publicado: (2021)

Successfully Treated Acute Fulminant Myocarditis Induced by Ulcerative Colitis with Extracorporeal Life Support and Infliximab
por: Kim, Han-Kyul, et al.
Publicado: (2016)

Infliximab in ulcerative colitis
por: Levin, Avi, et al.
Publicado: (2008)

Clinical Efficacy of Beclomethasone Dipropionate in Korean Patients with Ulcerative Colitis
por: Lee, Yoon Jee, et al.
Publicado: (2017)

Long-Term Clinical Outcomes of Korean Patient With Crohn's Disease Following Early Use of Infliximab
por: Kim, Nam Hee, et al.
Publicado: (2014)

Comparing the clinical outcomes of young-onset and adult-onset ulcerative colitis: a multi-center Korean Association for the Study for Intestinal Diseases study
por: Kim, Ji Yeon, et al.
Publicado: (2017)

Clinical Features of Ulcerative Colitis in Korea
por: Park, Seon Mee, et al.
Publicado: (1996)

Second Korean guidelines for the management of ulcerative colitis
por: Choi, Chang Hwan, et al.
Publicado: (2017)

Unmet Psychosocial Needs of Patients with Newly Diagnosed Ulcerative Colitis: Results from the Nationwide Prospective Cohort Study in Korea
por: Moon, Jung Rock, et al.
Publicado: (2020)

Quality of Life in Newly Diagnosed Moderate-to-Severe Ulcerative Colitis: Changes in the MOSAIK Cohort Over 1 Year
por: Jo, Ik Hyun, et al.
Publicado: (2022)

Additive effect of probiotics (Mutaflor) on 5-aminosalicylic acid therapy in patients with ulcerative colitis
por: Park, Soo-Kyung, et al.
Publicado: (2022)

Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment
por: Hyun, Hye Kyung, et al.
Publicado: (2022)

Adherence to Asacol once daily versus divided regimen for maintenance therapy in ulcerative colitis: a prospective, multicenter, randomized study
por: Park, Soo-Kyung, et al.
Publicado: (2019)

Corrigendum: Unmet Psychosocial Needs of Patients Newly Diagnosed with Ulcerative Colitis: Results from the Nationwide Prospective Cohort Study in Korea
por: Moon, Jung Rock, et al.
Publicado: (2021)

Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study
por: Shin, Seung Yong, et al.
Publicado: (2022)

Is Clostridium difficile infection a real threat in patients with ulcerative colitis? A prospective, multicenter study in Korea
por: Kim, Dae Bum, et al.
Publicado: (2018)

Pediatric Ulcerative Colitis: The Therapeutic Road to Infliximab
por: Puthoor, Pamela R., et al.
Publicado: (2013)

Changes in fecal metabolic and lipidomic features by anti-TNF treatment and prediction of clinical remission in patients with ulcerative colitis
por: Kim, Seok-Young, et al.
Publicado: (2023)

Comparative Evaluation between Sulfasalazine Alone and in Combination with Herbal Medicine on DSS-Induced Ulcerative Colitis Mice
por: Shin, Mi-Rae, et al.
Publicado: (2017)

Nanocomposites-based targeted oral drug delivery systems with infliximab in a murine colitis model
por: Kim, Jung Min, et al.
Publicado: (2020)

Remission of diffuse ulcerative duodenitis in a patient with ulcerative colitis after infliximab therapy: a case study and review of the literature
por: Choi, Yong-Sung, et al.
Publicado: (2019)

Clinical importance of weight gain and associated factors in patients with moderate to severe ulcerative colitis: results from the MOSAIK cohort in Korea
por: Yoon, Hyuk, et al.
Publicado: (2023)

Clinical Course of Infliximab Treatment in Korean Pediatric Ulcerative Colitis Patients: A Single Center Experience
por: Kim, Jong Min, et al.
Publicado: (2014)

Infliximab Therapy for Children with Moderate to Severe Ulcerative Colitis: A Step-Up versus a Top-Down Strategy
por: Kim, Mi Jin, et al.
Publicado: (2021)

Clinical Characteristics and Long-term Outcomes of Pediatric Ulcerative Colitis: A Single-Center Experience in Korea
por: Jang, Jooyoung, et al.
Publicado: (2022)

Infliximab: the evidence for its place in therapy in ulcerative colitis
por: Van Assche, Gert, et al.
Publicado: (2007)

Promising effect of infliximab on the extent of involvement in ulcerative colitis
por: Adibi, Peyman, et al.
Publicado: (2011)

Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update
por: Lawlor, Garrett, et al.
Publicado: (2009)

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
por: Fasanmade, Adedigbo A., et al.
Publicado: (2009)

Pericardial Effusion due to Infliximab Therapy for Ulcerative Colitis
por: Mirza, Muhammad, et al.
Publicado: (2018)

Early Serum Infliximab Levels in Pediatric Ulcerative Colitis
por: deBruyn, Jennifer C. C., et al.
Publicado: (2021)

Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn's Disease: A Nationwide, Multicenter Study
por: Choi, Chang Hwan, et al.
Publicado: (2016)

Epidemiology and Burden of Diabetic Foot Ulcer and Peripheral Arterial Disease in Korea
por: Chun, Dong-il, et al.
Publicado: (2019)

Clinical Characteristics and Long-term Prognosis of Elderly-Onset Ulcerative Colitis in a Population-Based Cohort in the Songpa-Kangdong District of Seoul, Korea
por: Park, Sang Hyoung, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_04r5rp41d95hqu23573v26iila